MedTrace Logo

Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL)

NCT01273844 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2017-04-07

No results posted yet for this study

Summary

To evaluate the efficacy and safety of Vel-Dex therapy (bortezomib and dexamethasone) followed by autologous hematopoietic stem cell transplantation as an initial treatment in patients with newly diagnosed AL.

Conditions

  • Amyloidosis

Interventions

DRUG

Bortezomib

Bortezomib

Sponsors & Collaborators

  • Soochow University

    collaborator OTHER

  • Nanjing Medical University

    collaborator OTHER

  • Zhi-Hong Liu, M.D.

    lead OTHER

Principal Investigators

  • zhihong Liu, Master · Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-01
Primary Completion
2016-05-12
Completion
2016-05-12

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01273844 on ClinicalTrials.gov